SCHEMBL18377692

SCHEMBL18377692

CCN1CCC(n2cnc(C)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
JAK1 P23458 1/20 0.40
GRM2 Q14416 1/20 0.39
HRH3 Q9Y5N1 3/20 0.38
KMT2A Q03164 1/20 0.37
SLC6A4 P31645 1/20 0.35
KDM2B Q8NHM5 1/20 0.35
KDM4A O75164 1/20 0.33
KDM4B O94953 1/20 0.33
KDM5C P41229 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
LRRK2 Q5S007 1/20 0.33
TLR9 Q9NR96 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
PRKCG P05129 1/20 0.33
PRKCB P05771 1/20 0.33
SRC P12931 1/20 0.33
PRKCA P17252 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19732428 0.83 CPB2 (0.32) DRD2DRD4DRD3GRM2
SCHEMBL18377886 0.82
SCHEMBL27389517 0.81 KDM2B (0.49) DRD2DRD4DRD3JAK1GRM2
SCHEMBL22860588 0.80 DRD2 (0.39) DRD2DRD4DRD3GRM2SLC6A4
SCHEMBL18367608 0.80 DRD2 (0.40) DRD2DRD4DRD3JAK1HRH3
SCHEMBL19589366 0.80 DRD2 (0.40) DRD2DRD4DRD3JAK1HRH3
SCHEMBL20325978 0.78 CDK5 (0.39) DRD2DRD4DRD3GRM2KDM2B
SCHEMBL9965935 0.75 CHRNB2 (0.39) JAK1KMT2AKDM2BTLR9TLR7
SCHEMBL14647026 0.75 CPB2 (0.42) DRD2DRD4DRD3JAK1GRM2
SCHEMBL15451921 0.74 KMT2A (0.39) DRD2DRD4DRD3JAK1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815818-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2017-11-14 US disclosed
US-20170008873-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008873-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS DRD2 4763/4885DRD4 4722/4885DRD3 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.